CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $67.85 Consensus PT from Brokerages

CRISPR Therapeutics AG (NASDAQ:CRSP) has earned a consensus recommendation of “Hold” from the twenty-two brokerages that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $67.85.

Several research analysts recently commented on the company. Bank of America cut their price target on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a report on Wednesday, January 21st. Chardan Capital cut their target price on CRISPR Therapeutics from $82.00 to $74.00 and set a “buy” rating on the stock in a research report on Wednesday, November 26th. Royal Bank Of Canada increased their target price on CRISPR Therapeutics from $42.00 to $50.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 11th. Finally, Citizens Jmp dropped their price target on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a research note on Friday, January 30th.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 60,000 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $60.23, for a total value of $3,613,800.00. Following the sale, the chief executive officer owned 134,201 shares in the company, valued at approximately $8,082,926.23. This represents a 30.90% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Trading of CRISPR Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Thurston Springer Miller Herd & Titak Inc. lifted its holdings in CRISPR Therapeutics by 196.9% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock worth $30,000 after buying an additional 382 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new stake in shares of CRISPR Therapeutics during the 2nd quarter valued at approximately $33,000. Thompson Investment Management Inc. bought a new position in CRISPR Therapeutics during the third quarter worth $33,000. Optiver Holding B.V. boosted its holdings in CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after purchasing an additional 210 shares during the period. Finally, Strategic Advocates LLC bought a new stake in CRISPR Therapeutics during the third quarter valued at $34,000. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Trading Up 1.3%

Shares of CRSP stock opened at $52.00 on Friday. The firm has a fifty day simple moving average of $55.05 and a 200-day simple moving average of $58.18. The company has a market capitalization of $4.96 billion, a PE ratio of -9.30 and a beta of 1.72. CRISPR Therapeutics has a twelve month low of $30.04 and a twelve month high of $78.48.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.15. The firm had revenue of $0.89 million for the quarter, compared to the consensus estimate of $8.74 million. CRISPR Therapeutics had a negative net margin of 1,273.70% and a negative return on equity of 21.23%. Equities research analysts predict that CRISPR Therapeutics will post -5.16 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.